We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Ondansetron Nausea & vomiting Film-coated tablets 4 and 8 mg
Ondansetron Nausea & vomiting Orodispersable tablets 4 and 8 mg
Otilonium bromide Irritable bowel syndrome Film-coated tablets 40 mg
Paracetamol / Tramadol Analgesic Effervescent tablets 325/37.5 mg
Partnena® Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states Jan 2014
Pramipexol Parkinson's Tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Prasugrel Base Prophylaxis and therapy of thrombosis Film-coated tablets 5 and 10 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetidia® Useful for the management of anxiety disorders Sep 2014
Quetidia® oral solution Useful for the management of anxiety disorders Sep 2017
Rasagiline Parkinson's Tablets 1 mg
Risperidone Psychosis, schizophrenia, bipolar disoder Film-coated tablets 0.5, 1, 2, 3, 4 and 6 mg
Rivaroxaban Thrombosis, stroke Film-coated tablets 10, 15 and 20 mg
Rizatriptan Migraine Orodispersable tablets 5 and 10 mg
Seripnol® Useful to promote relaxation and sleep Mar 2012
Seripnol® drops Useful to promote relaxation and sleep Apr 2014


Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Solifenacin Overactive bladder, urinary incontinence Film-coated tablets 5 and 10 mg
Sultiame * Epilepsy, convulsions Film-coated tablets 50, 100 and 200 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.